ReviewNan fang yi ke da xue xue bao = Journal of Southern Medical University2022
[An update of understanding of the hepatic vascular system and new research strategies].
Review in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Leukocyte cell-derived chemotaxin 2 (LECT2) regulates liver ischemia-reperfusion injury.Liver research (Beijing, China) · 2024Article
- Dynamics of glutamine synthetase expression in hepatic ischemia-reperfusion injury: Implications for therapeutic interventions.World journal of hepatology · 2024Article
- Exploring the metastasis-related biomarker and carcinogenic mechanism in liver cancer based on single cell technology.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the portal vessels, liver sinusoids, and central vessels are known to contain microvessels with different structures and functions, their changes and roles in liver fibrogenesis have not been fully understood. Recent studies suggest that in mouse models of liver fibrogenesis, vascular changes can occur at a very early stage, and different liver vessels undergo different changes and play different roles, as shown by a decreased number of portal vessels, increased sinusoid capillarization and increased central vessels. The increase of portal vessels alleviates liver fibrosis, while the increase of central vessels and sinusoid capillarization aggravates liver fibrosis. A full understanding of the regulatory mechanisms of each of these vessels is vital for treatment of liver fibrosis. A combined regulation of different endothelial cell (EC) regulatory signaling pathways for vascular normalization may provide new strategies for liver fibrosis therapy. Further studies of the changes and functions of blood vessels in different liver diseases, liver development and regeneration may bring about important breakthroughs. This review summarizes the changes of 3 hepatic microvessels and their roles in liver fibrogenesis and propose the major directions of future studies in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.